Nogaki F, Muso E, Yashiro M, Kasuno K, Kamata T, Ono T, Sasayama S
Department of Cardiovascular Medicine, Kyoto University, Graduate School of Medicine, Japan.
Kidney Int Suppl. 1999 Jul;71:S198-201. doi: 10.1046/j.1523-1755.1999.07151.x.
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have been demonstrated to suppress glomerular injuries in various renal diseases. These agents inhibit in vitro proliferation of several cell types, including mesangial cells. This effect indicates the ability to ameliorate mesangioproliferative lesions, independent of the improvement of hypercholesterolemia. On the other hand, it is not clear whether HMG-CoA reductase inhibitors directly regulate extracellular matrix (ECM) accumulation from mesangial cells.
In this study, to examine the in vitro effects of simvastatin, an HMG-CoA reductase inhibitor, on mRNA expressions of matrix proteins, growth factors, and matrix turnover proteins, we incubated cultured murine mesangial cells stimulated by fetal calf serum (FCS) with or without simvastatin for 24 hours, and Northern analysis was performed.
Simvastatin showed a slightly suppressive effect on mRNA expression of type IV collagen and fibronectin and a slightly up-regulative effect on that of type I collagen, whereas mRNA expression of type III collagen was markedly up-regulated. mRNA expression of platelet-derived growth factor (PDGF)-B chain and PDGF receptor beta-subunit was suppressed, whereas that of transforming growth factor-beta (TGF-beta) was not affected by simvastatin. Concerning matrix turnover proteins, simvastatin markedly reduced mRNA expression of plsminogen activator inhibitor-1 (PAI-1) without affecting the expression of tissue-type plasminogen activator (tPA).
These results suggest type-specific modulation of matrix protein production independent of TGF-beta and the suppressive effects of autocrine PDGF by administration of HMG-CoA reductase inhibitors in mesangial cells. Moreover, the beneficial effects of these agents on matrix protein accumulation may be through promoting ECM degradation derived from PAI-1 suppression.
3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂已被证明可抑制各种肾脏疾病中的肾小球损伤。这些药物可抑制包括系膜细胞在内的多种细胞类型的体外增殖。这种作用表明其具有改善系膜增殖性病变的能力,而与高胆固醇血症的改善无关。另一方面,尚不清楚HMG-CoA还原酶抑制剂是否直接调节系膜细胞的细胞外基质(ECM)积累。
在本研究中,为了检测HMG-CoA还原酶抑制剂辛伐他汀对基质蛋白、生长因子和基质周转蛋白mRNA表达的体外作用,我们将培养的受胎牛血清(FCS)刺激的小鼠系膜细胞在有或无辛伐他汀的情况下孵育24小时,然后进行Northern分析。
辛伐他汀对IV型胶原和纤连蛋白的mRNA表达有轻微抑制作用,对I型胶原的mRNA表达有轻微上调作用,而III型胶原的mRNA表达则明显上调。血小板衍生生长因子(PDGF)-B链和PDGF受体β亚基的mRNA表达受到抑制,而转化生长因子-β(TGF-β)的mRNA表达不受辛伐他汀影响。关于基质周转蛋白,辛伐他汀显著降低纤溶酶原激活物抑制剂-1(PAI-1)的mRNA表达,而不影响组织型纤溶酶原激活物(tPA)的表达。
这些结果表明,HMG-CoA还原酶抑制剂在系膜细胞中可对基质蛋白产生进行类型特异性调节,且不依赖于TGF-β,并具有自分泌PDGF的抑制作用。此外,这些药物对基质蛋白积累的有益作用可能是通过抑制PAI-1促进ECM降解来实现的。